Sunday, August 31, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Anticipated Earnings Report and Guidance for Cabot

Elaine Mendonca by Elaine Mendonca
February 2, 2024
in Breaking News
0
Finance_Banking (2)
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On February 2, 2024, Cabot (NYSE:CBT) is set to unveil its latest quarterly earnings report, which is highly anticipated by investors. The company’s performance in the previous quarter exceeded expectations, resulting in a significant boost to its share price. Analysts predict that Cabot will report an earnings per share (EPS) of $1.49 for the quarter ending in December 2023.

The market has observed that Cabot’s stock price is greatly influenced by its earnings and guidance. While an earnings beat or miss is not the sole determinant of stock price movement, the provided guidance and forecasted growth for the next quarter also play a crucial role. It is essential for investors to closely monitor the company’s earnings release and the subsequent guidance or forecast, as these factors are likely to have a substantial impact on the stock price.

As of January 31, 2024, Cabot’s shares were trading at $73.18, reflecting a 2.03% decrease over the past 52 weeks. This indicates the need for careful observation and analysis of the upcoming earnings report and guidance, as it may have implications for the stock’s performance.

For more detailed information, interested individuals can visit the earnings calendar on Benzinga’s website. Cabot is scheduled to report its earnings on February 5, 2024, after the market closes. Analysts are expecting the company to announce earnings of $1.49 per share for the quarter. Furthermore, Cabot has set its FY24 guidance at $6.30-6.80 EPS. Notably, in the previous quarter, Cabot surpassed analyst estimates by reporting quarterly earnings of $1.65 per share.

CBT Stock Price Drops on February 2, 2024: Analysis and Concerns for Investors

On February 2, 2024, CBT stock had a drop in price. According to data from CNN Money, the stock opened at $71.94, which was $1.24 lower than its previous close.

However, despite these indicators, CBT experienced a price decrease on February 2. The stock’s price dropped by $1.18, which represented a 1.61% decrease from the previous market close. This decline may have been disappointing for investors who were hoping for a positive price movement.

Overall, CBT stock’s performance on February 2, 2024, was marked by a decrease in price. While the stock was trading in the middle of its 52-week range and near its 200-day simple moving average, the drop in price may have been a cause for concern for investors. As with any investment, it is essential to carefully consider all available information and consult with a financial advisor before making any investment decisions.

CBT Stock Performance on February 2, 2024: Promising Growth in Net Income and EPS

CBT Stock Performance on February 2, 2024:

CBT’s total revenue for the past year stood at $3.93 billion, reflecting a 9.03% decrease compared to the previous year. However, the company managed to hold its total revenue flat since the last quarter, with reported revenues of $965.00 million.

Moving on to net income, CBT exhibited remarkable growth over the past year. With a net income of $437.00 million, the company witnessed a substantial 112.14% increase compared to the previous year. Additionally, the net income surged by an impressive 180.49% since the last quarter, reaching $230.00 million.

Furthermore, CBT’s earnings per share (EPS) also experienced substantial growth. The EPS for the past year was reported at $7.73, marking a remarkable 113.64% increase compared to the previous year. Similarly, the EPS surged by an astounding 185.98% since the last quarter, reaching $4.10.

CBT’s stock performance on February 2, 2024, appears promising, with notable increases in net income and EPS. While the total revenue experienced a slight decline over the past year, it remained stable since the last quarter.

Investors and stakeholders should closely monitor CBT’s future performance to assess its sustainability and growth potential. While the past year has seen remarkable growth in net income and EPS, it is crucial to analyze whether these positive trends will continue in the coming quarters. External factors such as market conditions, industry competition, and global economic trends may influence CBT’s future performance.

In conclusion, CBT’s stock performance on February 2, 2024, highlighted significant growth in net income and EPS, despite a slight decline in total revenue over the past year. These figures indicate the company’s ability to generate higher profits and improve its profitability per outstanding share. However, it is essential for investors to remain vigilant and monitor CBT’s future performance to assess its long-term sustainability and growth potential.

Tags: CBT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Anticipation Builds for Cheggs Quarterly Earnings Report

Finance_ Chart up

UnitedGuardian Inc Announces Impressive Dividend Increase and Commitment to Shareholder Value

Anticipating Air Products Chemicals Quarterly Earnings Report

Recommended

Axsome Stock

Axsome’s Alzheimer Candidate Holds Key to Billion-Dollar Valuation

1 week ago
Finance_Capitalistic

Cantor Fitzgerald Analyst Reiterates Overweight Rating on 89bio with 29 Price Target

1 year ago
MO stock news

Barclays PLC Shows Confidence in New Jersey Resources with Significant Increase in Holdings and Announcement of Dividend

2 years ago
Club membership cost

Flotek Industries Sees Surge in Stock Prices Following Q4 Financial Report

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe ADSK Alibaba AMD AMZN Apple AVGO BA Broadcom C Coinbase COST CRWD DIS DWAC Eli Lilly GM IBM INTC Intel Kraft Heinz LLY Lockheed META Micron MP Materials MSFT NFLX NIO Nvidia NVO Opendoor Oracle Palantir PLTR Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TGT Tilray TSLA
No Result
View All Result

Highlights

Aldeyra Therapeutics Achieves Dual Regulatory Milestones for Key Drug Candidates

Semler Scientific’s High-Stakes Bitcoin Bet Faces Mounting Pressure

Analysts Maintain Strong Buy Ratings for Curis Despite Stock’s Steep Decline

Jazz Pharmaceuticals Secures Dual Regulatory Wins for Oncology Drug

Leadership Transition at Simmons First National Amid Major Financial Restructuring

A Tale of Two Technologies: Cummins Navigates AI Boom and Green Transition

Trending

FactSet Research Stock
Analysis

FactSet Research Faces Critical Earnings Test Amid Market Pressures

by Robert Sasse
August 31, 2025
0

FactSet Research Systems finds itself at a pivotal juncture as it prepares to release fourth-quarter results on...

Victory Capital Stock

Victory Capital: A Stealthy Acquisition Powerhouse in Asset Management?

August 31, 2025
Paramount Stock

Paramount’s Strategic Reboot: A New Era with Skydance and UFC Partnership

August 31, 2025
Aldeyra Therapeutics Stock

Aldeyra Therapeutics Achieves Dual Regulatory Milestones for Key Drug Candidates

August 31, 2025
Semler Scientific Stock

Semler Scientific’s High-Stakes Bitcoin Bet Faces Mounting Pressure

August 31, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • FactSet Research Faces Critical Earnings Test Amid Market Pressures August 31, 2025
  • Victory Capital: A Stealthy Acquisition Powerhouse in Asset Management? August 31, 2025
  • Paramount’s Strategic Reboot: A New Era with Skydance and UFC Partnership August 31, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com